DCs generated with GM-CSF/IL-4 and matured with TNF-α, LPS, or CpG and DCs generated with Flt3L and matured with LPS produce AML-specific CTLp cells in vivo.
Cohorts of 8 to 10 mice were injected intravenously with DCs pulsed with AML (C1498) lysate (0.5 × 106 cells/mouse) 14 and 7 days prior to tumor challenge on day 0. On day 0, the 3 representative mice per group were killed, and the spleens were harvested for splenic C1498-reactive CTLp frequency estimate. The mean total splenic anti-AML CTLp number ± SEM is shown on the y-axis for each of the 4 groups and naive control. All methods of DC propagation and in vivo vaccination generated greater numbers of tumor-specific CTLps compared with naive controls (*P < .05,#P = .07). There were no substantial differences among the 4 different propagation methods. The irrelevant tumor controls, B16F10 and Yac-1, failed to stimulate a CTLp response, demonstrating tumor specificity in the DC vaccinated mice.
